单位：[1]Department of Surgery,University of California,San Diego,LaJolla,CA,USA[2]Department of Medicine,University of California,San Diego,LaJolla,CA,USA[3]Liver Research Center,Beijing Friendship Hospital,Capital Medical University,Beijing, China临床科室国家中心肝病分中心首都医科大学附属北京友谊医院[4]Department of Surgery,Graduate School of Medicine,Kyoto University,Kyoto,Japan
Liver fibrosis is a wound-healing process in response to repeated and chronic injury to hepatocytes and/or cholangiocytes. Ongoing hepatocyte apoptosis or necrosis lead to increase in ROS production and decrease in antioxidant activity, which recruits inflammatory cells from the blood and activate hepatic stellate cells (HSCs) changing to myofibroblasts. Injury to cholangiocytes also recruits inflammatory cells to the liver and activates portal fibroblasts in the portal area, which release molecules to activate and amplify cholangiocytes. No matter what origin of myofibroblasts, either HSCs or portal fibroblasts, they share similar characteristics, including being positive for alpha-smooth muscle actin and producing extracellular matrix. Based on the extensive pathogenesis knowledge of liver fibrosis, therapeutic strategies have been designed to target each step of this process, including hepatocyte apoptosis, cholangiocyte proliferation, inflammation, and activation of myofibroblasts to deposit extracellular matrix, yet the current therapies are still in early-phase clinical development. There is an urgent need to translate the molecular mechanism of liver fibrosis to effective and potent reagents or therapies in human.
基金：
NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01DK101737, R01DK099205] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [P42ES010337] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [P50AA011999, U01AA021856, U01AA022614] Funding Source: NIH RePORTER; NIAAA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [U01 AA021856, U01 AA022614, P50 AA011999] Funding Source: Medline; NIDDK NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01 DK101737, R01 DK099205] Funding Source: Medline; NIEHS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [P42 ES010337] Funding Source: Medline
第一作者单位：[1]Department of Surgery,University of California,San Diego,LaJolla,CA,USA[2]Department of Medicine,University of California,San Diego,LaJolla,CA,USA[3]Liver Research Center,Beijing Friendship Hospital,Capital Medical University,Beijing, China
通讯作者：
推荐引用方式(GB/T 7714)：
Wang Ping,Koyama Yukinori,Liu Xiao,et al.Promising Therapy Candidates for Liver Fibrosis[J].FRONTIERS in PHYSIOLOGY.2016,7:doi:10.3389/fphys.2016.00047.
APA：
Wang, Ping,Koyama, Yukinori,Liu, Xiao,Xu, Jun,Ma, Hsiao-Yen...&Kisseleva, Tatiana.(2016).Promising Therapy Candidates for Liver Fibrosis.FRONTIERS in PHYSIOLOGY,7,
MLA：
Wang, Ping,et al."Promising Therapy Candidates for Liver Fibrosis".FRONTIERS in PHYSIOLOGY 7.(2016)
